NCT07846956Not yet recruiting
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in Non-Diabetic Obese Patients Using Glucagon-Like Peptide-1 Receptor Agonists: A Retrospective Real-World Study
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as semaglutide and tirzepatide, are widely used for type 2 diabetes and obesity. Since 2023, case series, cohort studies and regulatory reviews have raised the possibility of an association between semaglutide and NAION, but published evidence is conflicting, and data in non-diabetic obese patients are limited. This retrospective, single-center, descriptive real-world study will review the existing records of non-diabetic obese adults (BMI \> 30) who used a GLP-1 RA and attended the ophthalmology outpatient clinic between January 2025 and February 2026 with at least two eye examinations. The aim is to describe the occurrence and time-related change of NAION and related ophthalmic findings in this population.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 28 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 21 Sept 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Istanbul Saglik Bilimleri University
- Diseases
- Obesity
- NCT number
- NCT07846956
What you commit to
- Study type: Observational
- Planned participants: 28
- From 21 Sept 2026 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous optic neuritis or similar eye disease
Other illness
- Diagnosis of hypertension
- Optic disc drusen, optic disc anomaly, glaucoma or other disease involving the optic nerve
Other
- High hyperopia or small, crowded optic disc
- Not meeting the inclusion criteria or not willing to participate
Who the study is looking for
- Age 18 years or older
- Diagnosis of obesity (body mass index \> 30)
- No hearing, speech or cognitive impairment
- Not receiving treatment for major depressive disorder and not using antidepressant medication
- At least two eye examinations with measurements on record
- Verbal agreement to participate
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kanuni Sultan Süleyman Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.